vrtx nasdaq - Search News

Vertex Pharmaceuticals, NASDAQ

Vertex Pharmaceuticals’s (NASDAQ:VRTX) Q4 Sales Top Estimates

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q4 CY2024 results , with sales up 15.7% year on year to $2.91 billion. The company expects the full year’s revenue to be around $11.88 billion,

YAHOO!Finance · 19h

Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) Intrinsic Value Is Potentially 50% Above Its Share Price

In this article we are going to estimate the intrinsic value of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by taking the expected future cash flows and discounting them to their present value.

The Motley Fool on MSN · 13h

Vertex Pharmaceuticals (VRTX) Q4 2024 Earnings Call Transcript

Operator Good day, and welcome to the Vertex Pharmaceuticals fourth quarter 2024 earnings call. All participants will be in a listen-only mode. [Operator instructions] Please note, this event is being recorded.

Zacks.com on MSN · 11h

Vertex Pharmaceuticals (VRTX) Misses Q4 Earnings Estimates

Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $3.98 per share, missing the Zacks Consensus Estimate of $3.99 per share. This compares to earnings of $4.20 per share a year ago. These figures are adjusted for non-recurring items.

Nasdaq5d

Is VRTX a Portfolio Must Have After Two FDA Nods Ahead of Q4 Earnings?

Vertex Pharmaceuticals Incorporated VRTX will report fourth-quarter and full-year 2024 earnings result on Feb. 10, after market close. The Zacks Consensus Estimate for sales and earnings for the ...

10h

Vertex's Revenue Surges but EPS Slips

Vertex provided a revenue guidance range of $11.75 billion to $12 billion for 2025, which would amount to an increase of 6.6% to 8.9%. Management anticipates continued strong performance from its ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Vertex Pharmaceuticals, NASDAQ

Trending now